Form 4: Tourmaline Bio Director Caley Castelein Reports Stock Option Grant

Director Caley Castelein of Tourmaline Bio, Inc. reports the acquisition of stock options.

Summary

• On June 5, 2024, Caley Castelein, a director of Tourmaline Bio, Inc., reported the acquisition of stock options.
• The transaction involved the grant of options to purchase 10,000 shares of common stock at an exercise price of $13.91 per share.
• The options vest on the earlier of the anniversary of the transaction date or the date of the Issuer's 2025 Annual Meeting of Stockholders, contingent upon continued service.
• Following the transaction, Castelein directly owns 10,000 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (stock option grant) which is generally viewed neutrally to positively as it aligns director interests with shareholders. There are no indications of negative sentiment.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule tied to continued service and the annual meeting is a typical structure to ensure ongoing commitment.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's performance leads to company growth.
• The grant incentivizes the director to act in the best interests of the company and its stakeholders.

Key Dates